XML 41 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Research Agreements (Details)
$ in Thousands, € in Millions
1 Months Ended 3 Months Ended 9 Months Ended
Feb. 21, 2013
Apr. 30, 2015
USD ($)
Apr. 30, 2015
EUR (€)
Feb. 28, 2013
USD ($)
Feb. 28, 2013
EUR (€)
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2016
USD ($)
Sep. 30, 2015
USD ($)
Research Agreements                  
Research and development expense           $ 27,453 $ 18,217 $ 81,827 $ 46,054
Clinical Trial Services Agreement | Abaloparatide-SC Phase 3 Extension Clinical Study | Nordic                  
Research Agreements                  
Amount reflected in accrued expenses and other current liabilities resulting from services payable in cash           2,200   2,200  
Clinical Trial Services Agreement | Letter of Intent | Abaloparatide-SC Phase 3 Extension Clinical Study | Nordic                  
Research Agreements                  
Additional term provided for standard-of-care treatment 18 months                
Clinical Trial Services Agreement | NB-3 Amendment | Abaloparatide-SC Phase 3 Extension Clinical Study | Nordic | Maximum                  
Research Agreements                  
Amount of euro-denominated payments required over the course of Clinical Trial   $ 4,600 € 4.1            
Clinical Trial Services Agreement | Clinical Trial Services Agreement | Abaloparatide-SC Phase 3 Extension Clinical Study | Per patient costs for enrolled patients                  
Research Agreements                  
Research and development expense           $ 700 $ 1,500 $ 2,600 $ 4,100
Clinical Trial Services Agreement | Clinical Trial Services Agreement | Abaloparatide-SC Phase 3 Extension Clinical Study | Maximum | Per patient costs for enrolled patients                  
Research Agreements                  
Period for which research and development expense is recognized               19 months  
Clinical Trial Services Agreement | Clinical Trial Services Agreement | Abaloparatide-SC Phase 3 Extension Clinical Study | Minimum | Per patient costs for enrolled patients                  
Research Agreements                  
Period for which research and development expense is recognized               9 months  
Clinical Trial Services Agreement | Clinical Trial Services Agreement | Abaloparatide-SC Phase 3 Extension Clinical Study | Nordic | Maximum                  
Research Agreements                  
Amount of euro-denominated payments required over the course of Clinical Trial       $ 13,300 € 11.9        
Amount of U.S. dollar-denominated payments required over the course of Clinical Trial       $ 1,100